BPC-157 Oral Capsules

Description

BPC-157 Oral Capsules offer the extensively studied Body Protection Compound-157 peptide in a convenient gastric-resistant capsule format designed specifically for oral route bioavailability research. While BPC-157 is traditionally supplied as a lyophilized powder for reconstitution, the oral capsule formulation addresses a growing area of scientific interest: the study of peptide stability and absorption through the gastrointestinal tract. Each bottle contains 60 capsules, providing researchers with sufficient material for extended oral administration protocols.

One of the defining characteristics of BPC-157 that makes it uniquely suited for oral delivery research is its inherent gastric stability. Unlike most peptides, which are rapidly degraded by stomach acid and digestive enzymes, BPC-157 is derived from a protein naturally present in human gastric juice and has demonstrated remarkable resistance to enzymatic hydrolysis in gastric conditions. Studies using simulated gastric fluid have shown that BPC-157 retains its structural integrity at pH levels as low as 1.5, conditions that would destroy most other peptide molecules within minutes. This stability profile is attributed to the peptide's proline-rich sequence, which confers resistance to cleavage by pepsin and other gastric proteases.

The capsules utilize a gastric-resistant (enteric-coated) shell designed to survive the acidic stomach environment and dissolve in the higher pH conditions of the small intestine. While BPC-157 itself demonstrates gastric stability, the enteric coating provides an additional layer of protection and ensures consistent release in the intestinal lumen, where the majority of peptide absorption occurs. This dual-protection approach — inherent peptide stability combined with formulation engineering — represents a methodologically robust approach to oral peptide delivery research.

Preclinical research on oral BPC-157 administration has produced noteworthy results. In rodent models of inflammatory bowel disease, oral BPC-157 treatment was associated with reduced colonic inflammation, accelerated mucosal healing, and improvement in disease activity scores. Gastrointestinal studies have shown that orally administered BPC-157 exerts cytoprotective effects throughout the digestive tract, including protection against NSAID-induced gastric lesions, alcohol-induced mucosal damage, and stress-induced intestinal barrier dysfunction. Researchers have also investigated the systemic effects of oral BPC-157, finding evidence of tissue-protective activity beyond the gastrointestinal tract in animal models.

For laboratories focused on oral peptide pharmacology, these capsules eliminate the reconstitution step and associated sterility concerns inherent in working with lyophilized powders. The pre-measured capsule format also provides improved dosing accuracy for oral administration studies, reducing the variability that can arise from manual preparation of oral solutions. Each capsule contains BPC-157 peptide at research-grade purity exceeding 98% as verified by HPLC analysis, encapsulated under cGMP conditions to ensure batch-to-batch consistency.

EU Shipping: Ships from Spain to all 27 EU countries within 24-48 hours. Free shipping on orders over €100. No customs delays — intra-EU shipment. Tracked courier.

Administration Protocol (No Reconstitution Required)

Unlike lyophilized vials, BPC-157 Oral Capsules require no reconstitution. The pre-measured enteric-coated capsules are designed for direct oral administration in preclinical research protocols.

• Format: 60 hard gelatin capsules with hypromellose phthalate enteric coating, per bottle.
• Peptide content: Each capsule contains a standardized dose of BPC-157 (see batch-specific COA for exact mcg content).
• Administration: Oral, intact capsule. Do not open, crush, or chew the capsules — this destroys the gastric-resistant coating and exposes BPC-157 to the stomach acid environment prematurely.
• Release profile: The enteric coating dissolves at pH >5.5, releasing the peptide in the proximal small intestine where absorption occurs.
• Timing: Typical research protocols administer capsules either fasted (30 minutes before food) or with light meal. Document feeding state in research notes — it affects gastric transit time and downstream pharmacokinetics.
• Compliance: The pre-measured capsule format eliminates dosing variability inherent in reconstituting and drawing liquid solutions.
• Storage of opened bottle: Reseal tightly after each use. Avoid extracting capsules with bare hands; use clean tongs or pour directly to avoid moisture transfer.

Stability & Bioavailability Data

• Gastric stability: BPC-157 demonstrates exceptional resistance to gastric acid degradation (pH 1.5+) due to its proline-rich sequence resistant to pepsin cleavage. The enteric coating provides an additional protective layer beyond the peptide's intrinsic stability.
• Capsule dissolution: Enteric coating dissolves at pH >5.5 (small intestine), typically 60-90 minutes post-administration in fasted state.
• Oral bioavailability: Published rodent studies have documented systemic BPC-157 activity following oral administration, indicating measurable absorption despite the molecular weight (1,419 Da). Local GI effects (gastric mucosal protection, intestinal barrier restoration) are well-documented in IBD and ulcer models.
• Plasma half-life: Approximately 30 minutes following systemic uptake, similar to injectable administration. Downstream tissue effects persist substantially longer.
• Shelf life: 18 months from manufacture date at room temperature (15-25°C) in sealed bottle, protected from light and moisture.
• Extended storage: Refrigerate at 2-8°C if storing beyond 6 months. Avoid freeze cycles — freezing can crack the enteric coating.
• Thermal limits: Avoid sustained temperatures above 30°C; the gelatin shell and enteric coating may degrade at higher temperatures.

Composition

• Active Peptide: BPC-157 (Body Protection Compound-157)
• Format: Gastric-resistant (enteric-coated) capsules
• Capsule Count: 60 capsules per bottle
• BPC-157 Molecular Formula: C62H98N16O22
• BPC-157 Molecular Weight: 1419.53 g/mol
• Purity: >98% (HPLC)
• Excipients: Microcrystalline cellulose, enteric coating (hypromellose phthalate)

Storage

• Store capsules at room temperature (15-25C) in a cool, dry place.
• For extended storage (beyond 6 months), refrigerate at 2-8C.
• Keep bottle tightly sealed when not in use.
• Avoid exposure to excessive heat, humidity, and direct sunlight.
• Shelf life: 18 months from manufacture date when stored properly.

Certificate of Analysis

Every batch of BPC-157 Oral Capsules sold by Pepspan undergoes rigorous third-party testing. Our Certificate of Analysis (COA) includes HPLC purity analysis of the peptide content, mass spectrometry confirmation, dissolution testing to verify enteric coating performance, content uniformity testing across capsule samples, and microbial limit testing. COA documentation is available upon request for any batch number. All testing is performed by independent European laboratories.

Current Batch: Pending first shipment

Every batch of BPC-157 Oral sold by Pepspan is independently tested by Janoshik Analytical (Prague, Czech Republic). HPLC purity analysis, mass spectrometry, and amino acid sequencing are performed for each shipment. Reports are batch-specific — not generic.

View All Purity Reports →

Research Disclaimer

This product is intended for laboratory research use only. It is not a drug, food, cosmetic, or dietary supplement. BPC-157 Oral Capsules are not approved for human or veterinary use by any regulatory agency. They must not be administered to humans or animals outside of approved clinical trials. By purchasing this product, you confirm that you are a qualified researcher and that this product will be used exclusively for legitimate scientific research purposes. Pepspan assumes no liability for any misuse of this product. All handling must comply with local regulations and institutional safety protocols.

Frequently Asked Questions

What is BPC-157 Oral?

BPC-157 Oral Capsules contain the Body Protection Compound-157 pentadecapeptide in a gastric-resistant (enteric-coated) capsule format for oral bioavailability research. Each bottle contains 60 capsules. The formulation pairs BPC-157's intrinsic gastric stability with enteric protection to ensure release in the small intestine.

Do BPC-157 oral capsules need reconstitution?

No. The oral capsule format eliminates the reconstitution step required for lyophilized vials. Capsules are pre-measured for consistent dosing and ready to use directly in oral administration research protocols. Each capsule contains a standardized BPC-157 amount with research-grade purity verified by HPLC.

What is the dose per capsule?

Each capsule contains a standardized dose of BPC-157 (typically 500 mcg). Refer to the batch-specific COA for exact peptide content. Published rodent oral protocols have used 10-50 mcg/kg/day. Researchers should consult primary literature for protocol-specific dosing in their experimental model.

Why use BPC-157 in oral capsule form vs injectable?

BPC-157 demonstrates exceptional gastric stability — unlike most peptides — due to its proline-rich sequence resistant to pepsin cleavage. This makes it uniquely suited for oral bioavailability research. The enteric coating provides additional protection, ensuring release in the small intestine where absorption occurs. Oral capsules also eliminate sterility concerns and provide more accurate dosing than reconstituted solutions.

How should BPC-157 oral capsules be stored?

Store capsules at room temperature (15-25°C) in a cool, dry place, tightly sealed. For extended storage beyond 6 months, refrigerate at 2-8°C. Avoid heat, humidity, and direct sunlight. Shelf life is 18 months from manufacture date when stored properly.

Can I buy BPC-157 oral capsules in Europe?

Yes. Pepspan ships BPC-157 Oral Capsules (60 capsules per bottle) across all 27 EU countries from Spain. Each batch undergoes HPLC purity testing, dissolution testing for enteric coating performance, and content uniformity verification. COA included. Research Use Only. Orders ship within 24-48 hours — no customs delays, intra-EU shipment.

Do I need a prescription for BPC-157 oral?

No. BPC-157 Oral Capsules are sold strictly as a research reference material for laboratory and in vitro / preclinical use. They are not approved as a pharmaceutical or dietary supplement and do not require a prescription in the EU when sold for research purposes only.

How do oral capsules compare to BPC-157 injectable?

The injectable lyophilized form (5mg vial) requires reconstitution with bacteriostatic water and is used for parenteral administration research. The oral capsule format is designed for gastrointestinal pharmacology studies — investigating local GI effects (gastric ulcer models, IBD models) and systemic bioavailability via the oral route. Both formats use the same peptide active at >98% purity.

Further Research Resources

Additional research articles, comparison guides, and laboratory protocols related to this peptide:

• BPC-157 recovery & healing research overview
• Buy BPC-157 in Europe — sourcing & COA guide
• BPC-157 frequently asked questions
• How to store research peptides properly